(1S,2S)-2-(2-{[3-(1H-1,3-benzodiazol-2-yl)propyl](methyl)amino}ethyl)-7-fluoro-1-(propan-2-yl)-1,2,3,4-tetrahydronaphthalen-2-yl 2-methoxyacetate hydrate

• ChemBase编号: 174612
• 分子式: C29H40FN3O4
• 平均质量: 513.6440032
• 单一同位素质量: 513.300285
• SMILES: c1(ccc2c(c1)[C@@H]([C@](CC2)(CCN(CCCc1[nH]c2c(n1)cccc2)C)OC(=O)COC)C(C)C)F.O
• Canonical SMILES: COCC(=O)O[C@]1(CCN(CCCc2nc3c([nH]2)cccc3)C)CCc2c([C@@H]1C(C)C)cc(cc2)F.O
• InChI: InChI=1S/C29H38FN3O3.H2O/c1-20(2)28-23-18-22(30)12-11-21(23)13-14-29(28,36-27(34)19-35-4)15-17-33(3)16-7-10-26-31-24-8-5-6-9-25(24)32-26;/h5-6,8-9,11-12,18,20,28H,7,10,13-17,19H2,1-4H3,(H,31,32);1H2/t28-,29-;/m0./s1
• InChIKey: CESRFELODBYOJE-OCPPCWRMSA-N

名称和登记号

名称

• IUPAC标准名: (1S,2S)-2-(2-{[3-(1H-1,3-benzodiazol-2-yl)propyl](methyl)amino}ethyl)-7-fluoro-1-(propan-2-yl)-1,2,3,4-tetrahydronaphthalen-2-yl 2-methoxyacetate hydrate
• IUPAC传统名: (1S,2S)-2-(2-{[3-(1H-1,3-benzodiazol-2-yl)propyl](methyl)amino}ethyl)-7-fluoro-1-isopropyl-3,4-dihydro-1H-naphthalen-2-yl 2-methoxyacetate hydrate
• 别名: Posicor Monohydrate; Ro 40-5967 Monohydrate; Methoxyacetic Acid (1S,2S)-2-[2-[[3-(1H-Benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl Ester Dihydrochloride Monohydrate; Methoxyacetic Acid (1S-cis)-2-[2-[[3-(1H-Benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl Ester Dihydrochloride Monohydrate; Ro 40-5967/001 Monohydrate; Mibefradil Dihydrochloride Monohydrate

登记号

• PubChem SID: 164230522
• PubChem CID: 71750729

理论计算性质

• Acid pKa: 12.543808
• 质子受体: 4
• 质子供体: 1
• LogD (pH = 5.5): 1.2434295
• LogD (pH = 7.4): 2.7534637
• Log P: 5.1569924
• 摩尔折射率: 139.7308 cm^3
• 极化性: 55.523674 Å^3
• 极化表面积: 67.45 Å^2
• 可自由旋转的化学键: 12
• 里宾斯基五规则: false

详细说明

Toronto Research Chemicals - M341800

Mibefradil Dihydrochloride is a nondihydropyridine calcium channel blocker with potent vasodilator but weak inotropic action. Mibefradil Dihydrochloride is used in the treatment of hypertension and chronic angina pectoris.

参考文献

• Osterrieder, W. et al.: J. Cardio. Pharmacol., 13, 754 (1989)
• Veniant, M. et al.: J. Cardio. Pharmacol., 21, 544 (1989)
• Hefti, F. et al.: Arzneim.-Forsch., 40, 417 (1989)